Evidence map›Paper›PMID 35051256›Full record

ArticleBMJ surgery, interventions, & health technologies2020

Use of data from the Vascular Quality Initiative registry to support regulatory decisions yielded a high return on investment.

Jack L Cronenwett, Erika Avila-Tang, Adam W Beck, Daniel Bertges, Jens Eldrup-Jorgensen, Frederic S Resnic, Nadezda Radoja, Art Sedrakyan, Andreas Schick, Josh Smale and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMJ surgery, interventions, & health technologies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. [The quality assurance and device register of the German Institute for Vascular Medicine Health Research (DGG) in the COVID-19 era, big data and artificial intelligence].Gefasschirurgie : Zeitschrift fur vaskulare und endovaskulare Chirurgie : Organ der Deutschen und der Osterreichischen Gesellschaft fur Gefasschirurgie unter Mitarbeit der Schweizerischen Gesellschaft fur Gefasschirurgie · 2022
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 2 countries.

Jack L CronenwettDepartment of Surgery, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA.ORCID 0000-0002-6920-1631
Erika Avila-TangCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland, USA.
Adam W BeckDepartment of Surgery, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Daniel BertgesDepartment of Surgery, University of Vermont College of Medicine, Burlington, Vermont, USA.
Jens Eldrup-JorgensenDepartment of Surgery, Maine Medical Center, Portland, Maine, USA.
Frederic S ResnicDepartment of Cardiology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Nadezda RadojaCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland, USA.
Art SedrakyanHealthcare Polcy and Research, Weill Cornell Medical College, New York, New York, USA.
Andreas SchickCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland, USA.
Josh SmaleB-D Bard, Franklin Lakes, New Jersey, USA.
Roberta A BlossW L Gore and Associates Medical Products Division, Flagstaff, Arizona, USA.
Peter PhillipsLombard Medical Ltd, Didcot, UK.
Melissa HasenbankMedtronic Inc, Minneapolis, Minnesota, USA.
Shengchun WangMedtronic Inc, Minneapolis, Minnesota, USA.
Danica Marinac-DabicCenter for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland, USA.
Gregory PappasCenter for Biologics Evaluation and Research, Food and Drug Administration Office of the Commissioner, Rockville, Maryland, USA.ORCID 0000-0001-9507-0674
United States Food and Drug Administration · USMedtronic (United States) · USCenter for Biologics Evaluation and Research · USCornell University · USDartmouth College · USLahey Medical Center · USLombard Medical (United Kingdom) · GBMaine Medical Center · USMatthew Larson Foundation · USUniversity of Alabama at Birmingham · USUniversity of Vermont · USW. L. Gore & Associates (United States) · US

Funding

FDA HHS U01 FD006936
6 · The paper itself

Abstract

backgroundReal-world data (RWD) from the Society for Vascular Surgery Vascular Quality Initiative (VQI) registry has been used to support US Food and Drug Administration (FDA) regulatory decisions regarding vascular devices. The variables of cost and time needed for these registry-based studies have not been previously compared to traditional, independent, industry studies that would otherwise have been conducted to support regulatory decisions.

objectivesTo determine the potential value (cost and time saving and return on investment) created by device evaluation studies using the VQI registry infrastructure.

methodsWe compared studies that used data from the VQI registry with estimated costs of independent industry studies (counterfactual studies) using an established model using design specifications determined by FDA reviewers.

resultsWe analyzed the initial six studies evaluating vascular devices for regulatory decisions using data from the VQI registry that generated evidence for four device manufacturers. Return on investment for these studies was estimated to be 143% and cost saving as 59% based on an actual per patient (with 5-year follow-up) cost of US$11K using VQI data versus US$26K from the counterfactual when averaged across all studies. Significant enrollment time savings (45%-71%) were also realized compared with industry-based estimates.

conclusionsThe use of RWD from the VQI registry in this study and the transcatheter valve treatment coordinated registry network in a prior study indicates that substantial value was added to device evaluation projects by the reuse of registry data, with additional potential savings if linked claims data can be used instead of costly long-term in-person follow-up.

Indexed as

device evaluationhealthcare costsreal world evidencevascular devices

Identifiers

PMID35051256
PMCPMC8749325
OpenAlexW3095715047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.